Insights for Investors
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Beyond Air, Inc. (XAIR) stock surged +6.00%, trading at $0.51 on NASDAQ, up from the previous close of $0.48. The stock opened at $0.48, fluctuating between $0.47 and $0.53 in the recent session.
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
Employees | 107 |
Beta | -0.113 |
Sales or Revenue | $1.16M |
5Y Sales Change% | 0% |
Fiscal Year Ends | March |
Sector | Healthcare |
Industry | Medical - Devices |
Beyond Air, Inc. (NASDAQ: XAIR) stock price is $0.51 in the last trading session. During the trading session, XAIR stock reached the peak price of $0.53 while $0.47 was the lowest point it dropped to. The percentage change in XAIR stock occurred in the recent session was 6% while the dollar amount for the price change in XAIR stock was $0.03.
The NASDAQ listed XAIR is part of Medical - Devices industry that operates in the broader Healthcare sector. Beyond Air, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Adam Newman
Chief Legal Officer & Gen. Counsel
Mr. Amir Avniel
Pres, Chief Bus. Officer & Director
Dr. Giora Davidai M.D.
Chief Medical Officer
Prof. Andrew R. Colin M.D.
Chief Medical Officer & Member of Scientific Advisory Board
Mr. Steven Adam Lisi
Chief Executive Officer & Chairman
Mr. Michael A. Gaul
Chief Operating Officer
Mr. Douglas Quinton Larson
Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Edward Barger
Head of Investor Relations
Ms. Rebecca Van Doren
Head of Sales
Ms. Kori-Ann Taylor
Head of Marketing
Dr. Andrew R. Colin M.D.
Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory Board
Mr. Duncan Fatkin
Chief Commercial Officer
Dr. Jeff Myers M.D., Ph.D.
Chief Medical Officer
XAIR's closing price is 71.89% higher than its 52-week low of $0.30 where as its distance from 52-week high of $2.36 is -78.44%.
Number of XAIR employees currently stands at 107.
Official Website of XAIR is: https://www.beyondair.net
XAIR could be contacted at phone 516 665 8200 and can also be accessed through its website. XAIR operates from 900 Stewart Avenue, Garden City, NY 11530, United States.
XAIR stock volume for the day was 318.85K shares. The average number of XAIR shares traded daily for last 3 months was 582.64K.
The market value of XAIR currently stands at $36.73M with its latest stock price at $0.51 and 72.19M of its shares outstanding.